10-Q: Adaptive Biotechnologies Reports Q3 Profit, Boosted by Genentech Termination

Adaptive Biotechnologies achieved net income in Q3 2025, driven by strong MRD revenue growth and a one-time revenue recognition from the Genentech collaboration termination.

Summary

• Total revenue increased by 102% to $94.0 million for the three months ended September 30, 2025, compared to $46.4 million in the prior year.
• Net income attributable to Adaptive Biotechnologies Corporation was $9.5 million for Q3 2025, a significant improvement from a net loss of $32.1 million in Q3 2024.
• Year-to-date (nine months ended September 30, 2025) revenue grew 56% to $205.3 million, and net loss decreased to $45.9 million from $125.8 million in the prior year.
• The Genentech collaboration agreement was terminated on August 13, 2025, effective February 9, 2026, leading to a $33.7 million increase in Immune Medicine collaboration revenue for Q3 2025 due to deferred revenue recognition.
• ClonoSEQ test volume increased by 38% to 27,111 tests in Q3 2025 and 37% to 75,549 tests year-to-date.
• Adjusted EBITDA turned positive, reaching $27.9 million for Q3 2025 and $8.0 million year-to-date.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth and achieved net income in Q3, driven by both core MRD business expansion and a significant one-time revenue recognition from the Genentech termination. While the loss of future Genentech milestones is a negative, the underlying MRD business performance and improved Adjusted EBITDA are positive indicators. The insider selling plans introduce some caution.

Positives

• Achieved net income of $9.5 million in Q3 2025, a substantial improvement from a $32.1 million net loss in Q3 2024.
• Total revenue increased by 102% in Q3 2025 and 56% year-to-date, demonstrating strong top-line growth.
• MRD revenue increased by 52% in Q3 2025 and 43% year-to-date, driven by a 38% increase in ClonoSEQ test volume.
• Expanded Medicare coverage for clonoSEQ in Mantle Cell Lymphoma (MCL) and a 17% increase in the Medicare Clinical Laboratory Fee Schedule rate to $2,007 per test, with MolDX episode pricing updated to $8,029.
• Adjusted EBITDA turned positive, reaching $27.9 million in Q3 2025 and $8.0 million year-to-date, indicating improved operational efficiency.
• Integration of clonoSEQ into electronic medical record systems (Epic System Corporation's Aura and Flatiron Health's OncoEMR) to enable easier test ordering.

Negatives

• Termination of the Genentech collaboration agreement means the company is no longer eligible for up to $1.8 billion in potential future milestone payments and tiered royalties.
• Immune Medicine service revenue decreased by 37% in Q3 2025 and 16% year-to-date, excluding the one-time collaboration revenue recognition.
• Cash, cash equivalents, and marketable securities decreased to $216.8 million as of September 30, 2025, from $256.0 million at December 31, 2024.
• Accumulated deficit increased to $1.35 billion as of September 30, 2025, from $1.30 billion at December 31, 2024.
• Several executive officers adopted Rule 10b5-1 trading plans for selling common stock.

Risks

• The termination of the Genentech Agreement may have a material impact on the business and financial condition, as the company may not enter into a similar collaboration agreement.
• Any future collaboration agreements may present risks related to control, independence, inconsistent economic interests, or harm to reputation.
• If no other collaboration agreements are secured, Immune Medicine revenue may consist solely of research product services, potentially not comparable to prior periods.
• Cessation of Immune Medicine R&D expenses associated with Genentech may result in less innovation and business growth, and other R&D efforts may not be successful.
• Reliance on collaborators and other third parties for development, clinical testing, and regulatory approval of products.
• Ability to achieve and maintain commercial market acceptance of current and future products, including coverage and reimbursement decisions.
• Uncertainty in realizing payments like milestone fees from customers.
• Ability to understand T-cell mediated response and develop products leveraging TCR-antigen binding data.

Future Outlook

Management expects MRD revenue to increase in the long term due to enhanced penetration in existing patient populations, expansion into new populations, and optimized payor coverage. Immune Medicine revenue is expected to decrease in the short term following the Genentech Agreement termination. Research and development expenses are expected to remain relatively consistent in the short term and decrease as a percentage of revenue in the long term. Sales and marketing expenses are expected to increase in absolute dollars in the long term but decrease as a percentage of revenue. General and administrative expenses are expected to moderately increase in the short term and decrease as a percentage of revenue in the long term. The company believes existing cash, cash equivalents, and marketable securities will be sufficient to fund operations for at least the next 12 months.

Management Comments

• We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities.
• We plan to utilize the existing cash, cash equivalents and marketable securities on hand primarily to fund both our commercial and marketing activities associated with clonoSEQ and our continued research and development initiatives related to drug discovery.
• We believe our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months.

Industry Context

The company operates in the rapidly evolving immune medicine and diagnostics sector, leveraging proprietary technologies to decode the adaptive immune system. The strong growth in MRD revenue and ClonoSEQ test volumes indicates increasing adoption of advanced diagnostic tools in oncology, aligning with broader trends towards personalized medicine and precision diagnostics. The termination of the Genentech collaboration highlights the inherent risks and dependencies in large pharmaceutical partnerships, a common challenge in the biotech industry where R&D efforts often rely on external funding and expertise. The company's focus on artificial intelligence and machine learning for TCR-antigen mapping positions it within the cutting-edge of drug discovery, a highly competitive area.

Stakeholder Impact

• Shareholders: Potential for increased value due to improved financial performance and strong MRD growth, but also risk from Genentech termination and potential dilution from future capital raises. Insider selling by executives could be a concern.
• Employees: Restructuring activities in 2024 involved one-time termination benefits, indicating past workforce adjustments. Future R&D efforts may be impacted by the Genentech termination.
• Customers: Continued development and commercialization of clonoSEQ and Adaptive Immunosequencing services. Expanded Medicare coverage benefits clinical customers.
• Creditors: The revenue interest liability to OrbiMed continues, with interest expense impacting profitability.

Next Steps

• Continue commercial and marketing activities for clonoSEQ.
• Continue research and development initiatives related to drug discovery.
• Evaluate the impact of new accounting pronouncements (ASU 2023-09 and ASU 2024-03).
• Potentially seek additional capital to fund business expansion or strategic investments.
• Genentech Agreement termination effective February 9, 2026.

Key Dates

Recommendation

While Adaptive Biotechnologies reported strong revenue growth and achieved net income in Q3 2025, largely due to a one-time revenue recognition from the Genentech collaboration termination, the long-term implications of losing potential $1.8 billion in future milestones and royalties are significant. The core MRD business shows promising growth with increased test volumes and expanded Medicare coverage, which is a strong positive. However, the decrease in Immune Medicine service revenue (excluding the Genentech impact) and the adoption of Rule 10b5-1 trading plans by multiple executives for selling shares introduce a degree of caution. The company's liquidity is deemed sufficient for 12 months, but future capital raises are a possibility. Given these mixed signals, a 'hold' recommendation is appropriate, advising investors to monitor the company's ability to develop new collaborations or significantly accelerate its internal drug discovery efforts to offset the Genentech loss, while continuing to capitalize on the strong performance of its MRD segment.

Keywords

Immune Medicine, MRD, clonoSEQ, Genentech, Biotechnology, Diagnostics, TCR-based therapies, Oncology, Financial Results, SEC Filing, ADPT